Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
YP2C9 genotyping may identify a subgroup of patients who have difficulty at induction of warfarin therapy and are potentially at a higher risk of bleeding complications. Expand
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
Findings provide new insights into the mechanism of flucloxacillin DILI and have the potential to substantially improve diagnosis of this serious disease. Expand
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
The ELF panel has good diagnostic accuracy in an independent validation cohort of patients with NAFLD and the addition of established simple markers augments the diagnostic performance across different stages of fibrosis, which will potentially allow superior stratification of patients for emerging therapeutic strategies. Expand
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies. Expand
Guidelines on the management of ascites in cirrhosis
The aim of this guideline is to review and summarise the evidence that guides clinical diagnosis and management of ascites in patients with cirrhosis, and is intended to inform practising clinicians. Expand
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
Pioglitazone therapy over a 12-month period in nondiabetic subjects with NASH resulted in improvements in metabolic and histologic parameters, most notably liver injury and fibrosis. Expand
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
It is confirmed that TM6SF2 minor allele carriage is associated with NAFLD and is causally related to a previously reported chromosome 19 GWAS signal that was ascribed to the gene NCAN. Expand
Incidence and Etiology of Drug-Induced Liver Injury in Mainland China.
Traditional Chinese medicines, herbal and dietary supplements, and antituberculosis drugs were the leading causes of DILI in mainland China and the annual incidence was estimated to be 23.80 per 100,000 persons; higher than that reported from Western countries. Expand
Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.
Class I and II HLA genotypes affect susceptibility to AC-DILI, indicating the importance of the adaptive immune response in pathogenesis. Expand
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH show clinically significant histological improvement that is reasonably likely to predict clinical benefit. Expand